Business
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
The primary objectives were achieved in cohort one BioLexa was well-tolerated with no treatment related adverse events Initiating Cohort 2 patient screening
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The primary objectives were achieved in cohort one\n BioLexa was well-tolerated with no treatment related adverse events\n Initiating Cohort 2 patient screening in September\n\n\nNEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema. \n\n \n \n \n \n \n \n\n \nBioLexa has been administered twice per day for 14 days to the first ten subjects within Cohort 1; The interim safety review indicates that BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed.\n\"Today's announcement represents a significant milestone for Hoth,\" stated Robb Knie, CEO of Hoth Therapeutics. \"We are very pleased by the Cohort 1 results and are proceeding as planned with submission and enrollment for Cohort 2 with atopic dermatitis patients later this year.\"\nAbout BioLexaBioLexa is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized, communities consisting of bacteria adhered to a surface (both biological and abiotic surfaces) and to other bacteria, and often with a protective extracellular matrix. Mature bacterial biofilms often result in chronic, recurrent infections that are difficult to treat due to the barrier effect of the biofilm that facilitates antibiotic resistance and avoiding immune system mechanisms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping the bacteria in a more susceptible state to antimicrobial therapy. This novel mechanism of action has the potential to broadly treat clinical manifestations resulting from Staphylococcal biofilm formation.\nAdditional information and updates on the BioLexa clinical trial can be found by visiting www.hoththerapeutics.com and ClinicalTrials.Gov. \nAbout Hoth Therapeutics, Inc.\nHoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atop...